{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-001180","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.000462+00:00","generated_at":"2026-05-26T05:27:09.364620+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclacel amends stock purchase agreement with interim CEO for up to $8M equity line; adds 6-month lock-up","bullets":["Purchase price amended to greater of closing bid at signing or prior to each purchase date.","Added 6-month lock-up on any Shares issued under the agreement.","Company retains right to direct David Lazar to buy up to $8,000,000 of common stock through Sep 30, 2026.","Shares issued in reliance on exemptions under Securities Act Section 4(a)(2) and Regulation S or D.","Lazar is interim CEO; lock-up applies for six months from issuance date of each tranche."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-001180","json":"https://secwatch.observer/filing/0001829126-25-001180.json","markdown":"https://secwatch.observer/filing/0001829126-25-001180.md","text":"https://secwatch.observer/filing/0001829126-25-001180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000182912625001180/0001829126-25-001180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000182912625001180/cyclacel_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:27:09.364620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}